How should nivolumab‑induced neurotoxicity be managed?

Management of Nivolumab-Induced Neurotoxicity

For nivolumab-induced neurotoxicity, immediately hold or permanently discontinue the drug based on severity grade, initiate corticosteroids (with dose escalation for higher grades), obtain urgent neurology consultation for grade ≥2 toxicity, and consider additional immunosuppression (IVIG or plasmapheresis) for severe or refractory cases.

Initial Assessment and Grading

Perform comprehensive neurologic evaluation at first sign of any neurotoxicity to determine severity grade, as management is strictly grade-dependent 1.

Diagnostic Workup by Grade

Grade 1 (Mild) Evaluation:

• Screen for reversible causes: diabetic screen, B12, folate, TSH, HIV 1
• Consider serum protein electrophoresis and autoimmune/vasculitic screening 1
• Consider MRI of spine with or without contrast 1
• Consider neurology consultation 1

Grade 2 (Moderate) Evaluation:

• All Grade 1 workup PLUS 1:
• MRI of spine (advised); MRI of brain if cranial nerve involvement 1
• Consider EMG/nerve conduction studies 1
• Neurology consultation strongly recommended 1

Grade 3-4 (Severe) Evaluation:

• Follow Guillain-Barré syndrome (GBS) diagnostic protocol 1
• Mandatory neurology consultation 1
• MRI brain with/without contrast for encephalitis evaluation 1
• Lumbar puncture if indicated (measure opening pressure, cell count, protein, glucose, Gram stain, culture, viral PCR) 1
• EEG for seizure activity 2

Management Algorithm by Severity Grade

Grade 1 (Mild Symptoms)

Drug Management:

• Have low threshold to hold nivolumab and monitor symptoms for one week 1
• If continuing therapy, monitor very closely for symptom progression 1

Treatment:

• Supportive care alone may be sufficient 1
• For neuropathic pain: gabapentin, pregabalin, or duloxetine 1

Grade 2 (Moderate Symptoms)

Drug Management:

• Hold nivolumab immediately and resume only when symptoms return to grade 1 1

Treatment:

• Initial observation OR initiate prednisone 0.5-1 mg/kg orally (if progressing from mild) 1
• For neuropathic pain: gabapentin, pregabalin, or duloxetine 1
• For mild neurological adverse events with deterioration: start methylprednisolone 1-2 mg/kg orally or IV 3

Grade 3-4 (Severe/Life-Threatening)

Drug Management:

• Permanently discontinue nivolumab 1, 3
• Do not rechallenge with immunotherapy 1

Immediate Actions:

• Admit patient to hospital with ICU-level monitoring capability 1
• Mandatory neurology consultation 1, 3

Corticosteroid Therapy:

• Initiate IV methylprednisolone 2-4 mg/kg daily 1
• Alternative: methylprednisolone 1 g daily for 3 days, followed by oral corticosteroid taper 1
• Taper over 4-6 weeks under close monitoring 3

Additional Immunosuppression (if no improvement within 2-3 days):

• IVIG 0.4 g/kg/day for 5 days (total dose 2 g/kg) 1
• OR plasmapheresis 1, 3
• Consider adding mycophenolate mofetil (MMF) for refractory cases 3
• For GBS-like or myasthenia-like symptoms: strongly consider plasmapheresis or IVIG 3

Specific Neurotoxicity Syndromes

Guillain-Barré Syndrome (GBS) or GBS-like Presentations

Management Approach:

• Discontinue nivolumab immediately 1
• Admit to inpatient unit with rapid ICU transfer capability 1
• Corticosteroids are not usually recommended for idiopathic GBS; however, in ICI-related forms, a trial is reasonable 1
• Start IVIG 0.4 g/kg/day for 5 days OR plasmapheresis PLUS concurrent corticosteroids (methylprednisolone 2-4 mg/kg/day) 1
• Frequent neurochecks and pulmonary function monitoring 1
• Monitor for concurrent autonomic dysfunction 1
• Nonopioid management of neuropathic pain 1
• Treatment of constipation/ileus 1

Encephalitis

Diagnostic Requirements:

• Neurologic consultation mandatory 1
• MRI brain with/without contrast (may reveal T2/FLAIR changes typical of autoimmune encephalopathies or limbic encephalitis, or may be normal) 1
• Lumbar puncture to exclude infectious causes 1

Treatment:

• Hold nivolumab 1
• Empirical antiviral (IV acyclovir) and antibacterial therapy until CSF results available 1
• Once bacterial/viral infection excluded: oral prednisone 0.5-1 mg/kg OR IV methylprednisolone 1 mg/kg for moderate/severe symptoms 1
• For severe cases: high-dose methylprednisolone 1-2 mg/kg 3
• Case reports demonstrate rapid response to steroids plus IVIG in severe cases 4, 5

Aseptic Meningitis

Diagnostic Workup:

• MRI brain with/without contrast and pituitary protocol 1
• Cortisol (AM) and ACTH to rule out adrenal insufficiency 1
• Lumbar puncture: may show elevated WBC with normal glucose, normal culture/Gram stain, reactive lymphocytes or histiocytes on cytology 1

Treatment:

• Hold nivolumab 1
• Empirical antiviral/antibacterial therapy until CSF results 1
• Once infection excluded: close monitoring off corticosteroids OR oral prednisone 0.5-1 mg/kg or IV methylprednisolone 1 mg/kg for moderate/severe symptoms 1

Peripheral Neuropathy

Management:

• For mild symptoms: consider steroids 6
• For acute inflammatory demyelinating polyneuropathy (AIDP)-type picture: consider IVIG 6
• Symptomatic treatment with gabapentin, pregabalin, or duloxetine 1

Critical Monitoring and Supportive Care

Neurologic Assessment:

• Perform neurologic assessment and grading at least twice daily for grade ≥2 toxicity 2
• Include cognitive assessment and motor weakness evaluation 2

Repeat Imaging:

• Consider repeat neuroimaging (CT or MRI) every 2-3 days if persistent grade ≥3 neurotoxicity 2

Additional Precautions:

• Aspiration precautions and IV hydration 2
• Use caution with CNS-depressing medications (except those for seizure prophylaxis/treatment) 2
• Assess for papilledema or elevated intracranial pressure 2
• If elevated intracranial pressure excluded, diagnostic lumbar puncture may be considered for grade 3-4 neurotoxicity 2

Antifungal Prophylaxis:

• Strongly consider in patients receiving steroids for neurotoxicity treatment 2

Common Pitfalls and Caveats

Timing of Onset:

• Neurotoxicities can occur early (median 5 weeks, range 1-72 weeks) 7
• Remain vigilant throughout treatment course and even after discontinuation 7, 8

Severity and Progression:

• Neurotoxicities are often rapidly progressive 7, 9
• Early recognition and prompt treatment substantially prevent morbidity and mortality 7, 8
• Grade 3-4 severity negatively impacts overall survival 7

Steroid Considerations:

• If dexamethasone used for prophylaxis of cytokine release syndrome (in other contexts), there may be increased risk of grade 4 and prolonged neurologic toxicities 2
• Fast taper should be used when improvement occurs 2

Concurrent Conditions:

• Rule out pre-existing neurological diseases (e.g., Charcot-Marie-Tooth disease) in cases of severe motor involvement 10
• Exclude other causes: infections, metabolic derangements, paraneoplastic syndromes 1

Treatment Response:

• Most patients (16 of 18 in one series) improve with discontinuation of ICIs and steroids, with additional immunomodulation required in 50% 7
• Symptoms often improve rapidly (within 1-2 days) with appropriate treatment 4, 5

Rechallenge Considerations:

• Do not resume nivolumab for grade 3-4 neurotoxicity 1
• For grade 2 toxicity, only resume when symptoms return to grade 1 1